Adaptive Strategies That Accelerate Milestones and De-Risk Regulatory Approval
Phase 1 oncology trials are undergoing a major shift. Traditional 3+3 designs no longer meet regulatory expectations for dose optimization or the complexity of next-generation therapies. Sponsors now need richer early dose-finding data, broader dose exploration, and stronger justification for recommended Phase 2 doses.
What This eBook Covers
- The move beyond 3+3 designs and how Project Optimus is reshaping dose-finding
- Modern model-assisted designs (BOIN, mTPI-2, Bi3+3) and when to use them
- Practical frameworks to select the right Phase 1 design based on modality, safety profile, regulatory needs, and operational readiness
What You’ll Gain
- Avoid weak dose-finding strategies that slow development
- Improve alignment with Project Optimus and global regulatory requirements
- Accelerate timelines with smarter design and build a stronger evidence base for later-phase decisions
Download your copy to design smarter, faster, and more robust Phase 1 trials.
Offered Free by: Precision For Medicine
See All Resources from: Precision For Medicine
